Impact of Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent

Overview

The purpose of this study is to determine the safety profile of oral iron supplementation (OIS) with Sprinkles in a pediatric population with high prevalence of Iron deficiency (ID) and moderate or severe malnutrition (MSM); the efficacy profile will also be investigated.

Full Title of Study: “Impact of Oral Iron Supplementation With Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent – A Non-Inferiority Safety Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 2009

Detailed Description

Iron deficiency (ID) affects many children in developing countries. Anemia and impaired brain development are its most significant consequences. These may be prevented by giving oral iron supplements (OIS), such as Sprinkles. ID treatment was controversial because high dose parenteral iron therapy is strongly associated with severe infections when given to severely malnourished children. Many studies have since demonstrated the safety of low dose OIS. WHO guidelines reflect this finding: population-wide iron supplementation campaign (PWISC), without prior screening, is recommended when ID prevalence is ≥ 40%. However, a gap in the safety evidence has been identified: children with moderate or severe malnutrition (MSM) are strikingly absent from the studies performed to date to investigate the link between OIS and infectious morbidities. In this context, PWISC may have unrecognized deleterious effects when the prevalence of MSM is high, since safety is assumed, but incorrectly extrapolated from available evidence. We wish to emphasize an additional concern with regards to safety studies published thus far: all were designed as superiority trials. In this context, it is statistically incorrect to conclude that failure to show a significant difference between iron and placebo means that their respective side-effect profiles are similar.

Interventions

  • Dietary Supplement: Oral Iron Supplement
    • Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
  • Dietary Supplement: Placebo
    • Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days

Arms, Groups and Cohorts

  • Active Comparator: 1
    • Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
  • Placebo Comparator: 2
    • Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days

Clinical Trial Outcome Measures

Primary Measures

  • A composite score based on the sum of all distinct episodes of diarrhea, dysentery and lower respiratory tract infections
    • Time Frame: 2 distinct and consecutive phases of 6 months each

Secondary Measures

  • Incidence of death and fever without a source [Safety]
    • Time Frame: 2 distinct and consecutive phases of 6 months each
  • Change in haemoglobin concentration after Sprinkles supplementation [Efficacy]
    • Time Frame: 2 distinct and consecutive phases of 6 months each

Participating in This Clinical Trial

Inclusion Criteria

  • children aged 12 – 24 months – moderate to severe malnutrition (MSM), defined as weight-for-age Z-score ≤ -2 based on the National Center for Health Statistics (NCHS) standards Exclusion Criteria:

  • severe anemia (hemoglobin ≤70g/L) – near normal hemoglobin concentration (>100g/L) – weight-for-height <-3 z-score (severe wasting) – kwashiorkor (defined as evidence of edema) – congenital abnormality or disease – treatment with iron supplements in the past 3 months – inclusion in a nutrition program in the past – chronic illness other than malnutrition.

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 2 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Hospital for Sick Children
  • Collaborator
    • Bangladesh Rural Advancement Committee
  • Provider of Information About this Clinical Study
    • Principal Investigator: Stanley Zlotkin, Chief, Global Child Health – The Hospital for Sick Children
  • Overall Official(s)
    • Stanley Zlotkin, MD, Principal Investigator, The Hospital for Sick Children, Toronto Canada

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.